[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2021 Global AFP Testing Market: US, Europe, Japan-Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities

March 2021 | 248 pages | ID: 2F0F11AAD43EN
Venture Planning Group

US$ 2,450.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This unique report from LeadingMarketResearch.com provides information and analysisnot available from any other published source.

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.

The report is available by section, and can be customized to specific information needs and budget.

During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the Alpha-fetoprotein testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 248 pages and 14 tables
I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Clinical Significance and Laboratory Practices
B. Instrumentation Review And Market Needs
  1. Abbott AxSYM
  2. Abbott Architect c4000
  3. Abbott Architect i2000 Series
  4. Abbott Architect ci8200 System
  5. Beckman Coulter UniCel Series
  6. Beckman Coulter Access
  7. Binding Site ESP600
  8. bioMerieux Mini Vidas
  9. Carolina Chemistries BioLis 24i
  10. DiaSorin Liaison
  11. Horiba ABX Pentra
  12. Inverness DS2
  13. J&J Vitros ECi/ECiQ
  14. J&J Vitros 3600
  15. J&J Vitros 5600
  16. Olympus AU5400
  17. Olympus AU3000i
  18. Olympus AU2700
  19. Roche Modular Analytics
  20. Roche Cobas Integra
  21. Roche Cobas Integra 400 Plus
  22. Roche Elecsys
  23. Roche Cobas c311
  24. Siemens ADVIA Centaur
  25. Siemens Dimension
  26. Siemens Dimension RxL Max
  27. Siemens Dimension Vista
  28. Siemens Immulite
  29. Siemens Stratus
  30. Tosoh AIA-Series
  31. Vital Diagnostics ATAC 8000
  32. Vital Diagnostics Envoy
C. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
  Overview
  ELISA
  Immunofiltration
  Particle-Membrane Capture Immunoassay
  Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
  Chemiluminescence
  Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
H. Affinity Chromatographu
    e. Liposome Flow-Injection Immunoassay
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
  PCR
  DAP-PCR
  Immuno-PCR
  QC-PCR
  CAR
  DNA
  HPA
  LCR
  NASBA
  QBR
  SDA
  3 SR, and others
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas
Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
E. Personal Testing

III. FRANCE: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

IV. GERMANY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

V. ITALY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VI. JAPAN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VII. SPAIN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST

by Market Segment

IX. U.S.A.: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XI. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

XIII. COMPETITIVE PROFILES

Abbott
Affymetrix
Beckman Coulter/Danaher
Becton Dickinson
bioMerieux
Bio-Rad
Cepheid
Diamedix
DiaSorin
Eiken Chemical
Elitech Group
Enzo Biochem
Fujirebio
Grifols
GSK Biologicals
Hologic
Leica Biosystems
Lonza
Ortho-Clinical Diagnostics
Perkin Elmer
Qiagen
Roche
Scienion
Sequenom
SeraCare
Siemens Healthineers
Takara Bio
Thermo Fisher
Wako


More Publications